• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

NICE recommends automated insulin delivery tech rollout in UK, Medtronic, Dexcom applaud

November 8, 2023 By Sean Whooley

MiniMed 780G with Guardian 4 Medtronic
The MiniMed 780G with the Guardian 4 sensor. [Image courtesy of Medtronic]
An independent committee of the National Institute for Health and Care Excellence (NICE) voiced support for closed-loop insulin delivery.

The UK-based institute recommended offering automated insulin delivery (AID) for people whose type 1 diabetes is not controlled with their current device despite best possible management with an insulin pump or real-time or intermittently scanned continuous glucose monitoring (CGM).

Hybrid closed-loop systems utilize a CGM attached to the body that sends data to a body-worn insulin pump. They calculate the necessary insulin delivery to the body to keep blood glucose levels within a healthy range.

NICE, with NHS England, agreed to first offer hybrid closed-loop systems to certain people who already have an insulin pump. These include all children, young people, and women who are pregnant or planning a pregnancy. It comprises part of a five-year rollout plan.

Others eligible include adults with an average HbA1c reading of 7.5% or more and adults who suffer disabling hypoglycemia. Mark Chapman, NICE interim director of medical technology, says the technology represents “the best intervention” to control diabetes, barring a cure. NICE expects to publish its final guidance in December 2023.

“Using hybrid closed loop systems will be a game changer for people with type 1 diabetes,” said Jonathan Benger, NICE chief medical officer. “By ensuring their blood glucose levels are within the recommended range, people are less likely to have complications such as disabling hypoglycemia, strokes and heart attacks, which lead to costly NHS care. This technology will improve the health and wellbeing of patients, and save the NHS money in the long term.”

Diabetes and insulin delivery tech leaders applaud the NICE recommendation

Que Dallara, EVP & President, Medtronic Diabetes, wrote a LinkedIn post titled “Bravo, NICE! Yes, AID should be available for all.” In it, she called the recommendation an “exciting move” that reinforces the need to look beyond just CGM to manage diabetes. Medtronic develops the MiniMed 780G, its latest-generation automated insulin delivery system.

Dallara said AID systems are “one of the most remarkable medical achievements of the 21st century.” She believes people from all walks of life can “almost effortlessly harness [AID’s] potential for better health.”

“Providing a glucose number tells you where your sugars are, but not how to manage them,” Dallara wrote. “Like other areas of our life, automation can help to simplify diabetes management, and it’s difficult to match the efficiency and accuracy of automated technology. Outcomes are better. Quality of life is better.”

In a news release, Dexcom, which provides CGM for closed-loop insulin delivery systems, provided market research supporting the use of hybrid closed-loop systems. The company says 79% of people struggle to keep glucose levels in range and 45% don’t understand what a hybrid closed-loop system is.

Dexcom also noted that 99% of healthcare providers expect the NICE decision to “somewhat or significantly” change lives for the better.

“It is clear from our research that so many more people could benefit from HCL,” said Karen Baxter, VP for UK, Ireland, Benelux, Spain and France for Dexcom. “Every single person (100%) surveyed with type 1 diabetes said that being on an HCL system has reduced the burden of managing their diabetes and 98% of healthcare practitioners say they would want all people with type 1 diabetes to have access to HCL. The newly announced TA from NICE is a great advancement in access to diabetes technology.

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: Dexcom, Medtronic, NICE

IN CASE YOU MISSED IT

  • Medtronic to separate Diabetes business unit
  • Tandem Diabetes Care wins CE mark for Mobi insulin pump with Control-IQ+ technology
  • Glooko adds chief strategy officer to chief medical officer’s title
  • Cordis launches 10,000-patient registry for drug-eluting balloon
  • Senseonics opens $50M public offering, $25M private placement with Abbott

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS